Geron Corp
corporate_fare Company Profile
Geron Corp (NASDAQ:GERN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for GERN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for GERN spans 10-Q, 8-K, DEF 14A, S-3ASR.
Recent high-impact activity:
- Geron 10-Q: Q3 Profit on $60.1M RYTELO Sales, $339.4M Cash After IMpactMF Wind-Down
- Geron Swings to Q3 Profit on $60.1M RYTELO Revenue, Cuts 2026 Opex Guidance
- Geron Swings to Profit as RYTELO Revenue Hits $60.1M, Opex Guidance Cut
- Geron Scraps Phase 3 Myelofibrosis Trial After DMC Says Survival Endpoint Unlikely
- Geron Q2 Revenue Jumps 17% to $57.5M; Loss Narrows; Cash Runway Extended
Financial Snapshot
Short Interest & Short Volume
3.92 days to coverFINRA reported short interest of 66,951,283 shares in GERN as of the October 30, 2026 settlement, a 10.3% decrease from the prior period — about 3.9 days to cover at its recent average daily volume. On November 20, 2026, 66.7% of GERN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.